This year, Forbion's Excellence Roundtable theme focused on the potential of advanced therapies to revolutionise medicine.
Advanced therapies are on the cusp of being used much more broadly: moving beyond rare diseases and into inflammatory auto-immune conditions like inflammatory bowel disease, rheumatoid arthritis and multiple sclerosis. Scaling these therapies requires continued reductions in manufacturing costs, advances in production capacity, and regulatory innovation to support new clinical trial endpoints.
Realising their full potential will also depend on sustainable reimbursement models that address high upfront costs while recognising their long-term clinical and economic value.
Panelists:
- Sander van Deventer, M.D., PhD - Operating Partner, Forbion
- Clive Meanwell, M.B., Ch.B., M.D. - Co-CEO, Corsera Health
- Sam Fazeli - Director of Research, Global Industries, Bloomberg Intelligence
- Geert-Jan Mulder, MD - Managing Partner, Forbion
- Elena Ritsou, PhD - CEO, Moirea
Moderator:
- Charis Gresser - Former FT Journalist